General description
Lysophosphatidic acid (LPA) belongs to a class of phospholipids, that has a glycerol backbone attached by a phosphate group, an aliphatic chain and a hydroxyl group. It has a phosphate group attached to sn-3 position, an aliphatic chain attached to sn-1 or sn-2 position and the hydroxyl group attached to the remaining sn-1 or sn-2 position. 06:0 Lyso PA/HHGP, belongs to the LPA (lysophosphatidic acid) family. It is a negatively charged single chain lipid.
Lysophosphatidic acid (LPA) has a free hydroxyl and phosphate moiety. It is hydrophilic and is not associated with the membrane. It is the major constituent of serum.
Application
06:0 Lyso PA (LPA) has been used in the structure-activity relationship (SAR) analysis with G-protein receptor GPR92. It has also been used in lipid assay in the treatment of serum-starved primary mouse embryonic fibroblast cells.
06:0 Lyso PA has been used to study the role of lipid binding to MxiM protein in co‐crystallization experiments.
Biochem/physiol Actions
Lysophosphatidic acid (LPA) participates in several biological functions. LPA stimulates platelet aggregation, chemotaxis, cytoskeleton rearrangement, Ca2+ mobilization and cell proliferation. 06:0 Lyso PA/HHGP possesses a micromolar binding affinity for global regulator of LEE (locus of enterocyte effacement) repressor (GrlR) and for β-lactoglobulin.
Lysophosphatidic acid (LPA) is the precursor for the synthesis of phospholipids in eukaryotes and prokaryotes. It acts as an intercellular signaling molecule. Activated platelets produce LPA. It plays a major role in tissue healing and wound regeneration. LPA binds to G-protein coupled receptors. It possesses mitogenic properties. LPA inhibits differentiation of neuroblastoma and myoblast, aids in neurotransmitter release and smooth muscle contraction. It is a potential biomarker for ovarian and gynecological cancers. It is implicated in the initiation of neuropathic pain.
Packaging
5 mL Amber Glass Screw Cap Vial (857119P-25mg)